Can­cer cell-based ther­a­pies com­ing in­to 'im­por­tan­t' year for R&D, say SVB an­a­lysts

De­spite in­vestor doubt in al­lo­gene­ic cell ther­a­py, 2023 will be an “im­por­tant” year for both au­tol­o­gous and al­lo­gene­ic im­mune-cell-based ther­a­pies in mul­ti­ple myelo­ma and non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.